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Abstract: A new series of specifically substituted cyclohepta[b]indole derivatives from the precursor thiophen-2-ylmethylene has been 
synthesized. The structures of synthesized derivatives were established by spectral and elemental analyses. The docking studies with protein 
kinase CK2 was performed, derivative 6c exhibited the most excellent glide and E model score of –7.61 and –58.27, respectively. In-vitro 
anticancer activity against cervical cancer cell line (HeLa) was studied. The IC50 values were compared with the standard drug Ellipticine. 
Compounds 5c, 6c and 6d showed better IC50 value when compared to the other molecules. The derivatives were evaluated for their 
antibacterial activity against the reference drugs Sparfloxacin and Norfloxacin using agar dilution method. The derivatives 4a–d exhibited better 
MIC values against Gram-positive bacteria and Gram-negative bacteria when compared with remaining derivatives. Structure activity 
relationship (SAR) analyses established that the derivatives are potential lead compounds for future drug development studies. 
 





ON communicable diseases (NCDs) such as cancer, 
heart disease and diabetes account for about 65% of 
the world’s deaths. The global cancer burden is growing at 
an alarming rate. As per the latest information available, it 
is estimated that if cancer cases continue to increase at its 
present rate, in 2030 alone, about 21.6 million new cancer 
cases and 13.0 million cancer deaths would happen world-
wide (Cancer Facts & Figures 2017). According to the statis-
tics, cervical and breast cancers are the most commonly 
diagnosed cancers among women in most areas of the 
world.[1] 
 Current cancer treatments include surgery, radio-
therapy and chemotherapy. Some of the major chemother-
apeutic agents currently being used to treat cancer are 
Bleomycin, Avastin, Cisplatin and Docetaxel. The search for 
potent, harmless and selective anticancer compounds is a 
crucial aspect of modern cancer research. On the other 
hand, treatment of bacterial infections still remains a major 
and challenging therapeutic problem, due to the emer-
gence of bacterial resistance to current therapeutic 
agents.[2] Therefore, there is a call for a new set of drugs in 
treating the pathogenic microorganisms and cancer caus-
ing cells. 
 Among the heterocyclic substructure the indole ring 
may be the most ubiquitous one. Owing to its great diver-
sity in both structure and biological activity, it is not surpris-
ing that the indole ring is an important structural 
component in many pharmaceuticals.[3–5] Particularly 
fused-polycyclic indole derivatives bearing a cyclo-
hepta[b]indole framework are potential candidates for 
drug discovery because this structural motif is present in a 
wide variety of biologically active alkaloids.[6–9] 
 The development of an efficient synthetic method of 
cyclohepta[b]indole derivatives has attracted broad atten-
tion in medicinal chemistry and synthetic organic chemis-
try. Extensive efforts are therefore focused on this  
topic.[10–13] Based on the promising therapeutic activities of 
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synthesize novel substituted cyclohepta[b]indole deriva-
tives. Furthermore, the newly synthesized compounds 
were evaluated for their active sites with protein kinase 
CK2 (casein kinase 2) by molecular docking study. The in 
vitro antibacterial and anticancer activity against HeLa 




All the chemicals and solvents were purchased from Sigma-
Aldrich and Merck, India. The melting points were checked 
in open capillaries and are uncorrected. Purity of the prod-
ucts was monitored on silica gel 60 F254 coated TLC plates. 
The FT-IR spectra of the samples were recorded on 
Shimadzu spectrophotometer in 4000-400 cm-1. 1H-NMR 
spectra: These were recorded on Bruker Avance III  
(400 MHz) and Bruker Avance-300 (300 MHz) spectrome-
ters. 13C-NMR spectra: These were recorded on Bruker 
Avance III (100.6 MHz) and Bruker Avance-300 (75.4 MHz) 
instruments. Elemental analysis was performed on an 
Elementar Vario EL III C-H-N analyser. 
General Procedure for the Synthesis of 
Compounds (3a–3d) 
A mixture of respective 7,8,9,10-tetrahydro-5H-cyclo-
hepta[b]indol-6-one (1a, 4 mmol) and thiophene-2-
carbaldehyde (2, 4 mmol) was treated with 4 % alcoholic 
KOH (15 mL) and the mixture stirred for 6 h at room 
temperature. The precipitated yellow crystalline product 
3a was filtered off and washed with rectified spirit. 





1.002 g (88 %); Yellow solid; m.p 162–165 °C; IR (KBr) νmax / 
cm–1: 3312 (N-H); 1623 (C=O); 1H NMR (300 MHz, CDCl3) δ / 
ppm: 2.14 (q, 2H, C9-H, J = 5.3 Hz), 3.02 (t, 2H, C8-H2, J = 5.6 
Hz), 3.13 (t, 2H, C10-H2, J = 4.7 Hz), 7.04–7.80 (m, 8H, C3’ 
C4’,C5’-thiophene-H, C2-methylene- H, C1,C2,C3,C4-aromatic-
H), 9.02 (s, N-H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 25.4, 
26.4, 28.0, 112.4, 112.6, 121.7, 122.4, 126.3, 128.3, 128.4, 
129.8, 130.2, 133.4, 134.3, 135.1, 136.2, 138.3, 185.7; Anal. 
Calcd mass fractions of element, w / %, for C18H15NOS (Mr = 
293) are: C, 73.72; H, 5.11; N, 4.78; S, 10.94. Found: C, 




0.9957 g (85 %); Yellow solid; m.p 178–180 °C; IR (KBr) νmax / 
cm–1: 3319 (N-H), 1622 (C=O); 1H NMR (300 MHz, CDCl3)  
δ / ppm: 2.17 (q, 2H, C9-H, J = 5.7 Hz), 2.45 (s, C2-3H), 3.05–
3.09 (t, 2H, C8-H2, J = 5.7 Hz), 3.16-3.20 (t, 2H, C10-H2 , J =  
6.3 Hz), 7.11–7.86 (m, 7H, C3’,C4’,C5’-thiophene-H; C2-
methylene- H, C1, C3,C4-aromatic-H), 9.03 (s, N-H); 13C NMR 
(75.4 MHz, CDCl3) δ / ppm : 21.5, 25.4, 26.4, 28.0, 111.4, 
111.5, 120.5, 123.0, 127.4, 128.6, 128.9, 129.4, 129.5, 
132.8, 133.1, 136.8, 138.7, 185.4; Anal. Calcd mass 
fractions of element, w / %, for C19H17NOS (Mr = 307) are: 
C, 74.26; H, 5.53; N, 4.56; S, 10.42. Found: C, 74.33; H, 5.50; 




0.9832 g (81 %); Yellow solid; m.p 210–212 °C; IR (KBr) νmax / 
cm–1: 3294 (N-H), 1628 (C=O). 1H NMR (300 MHz, CDCl3) δ / 
ppm: 2.20-2.27 (q, 2H, C4-H, J = 5.5 Hz), 3.06-3.10 (t, 2H, C3-
H2, J = 4.7 Hz), 3.13-3.19 (t, 2H, C5-H2, J = 6.3 Hz), 7.12–7.89 
(m, 7H, C3’, C4’, C5’-thiophene-H; C2-methylene-H, C1, C3 ,C4- 
aromatic-H); 9.16 (s,N-H); 13C NMR (75.4 MHz, CDCl3) δ / 
ppm: 25.3, 26.3, 27.9, 113.1, 113.3, 122.4, 123.7, 127.3, 
129.3, 129.4, 129.8, 130.2, 133.2, 133.7, 135.1, 136.3, 
138.7, 185.4; Anal. Calcd mass fractions of element, w / %, 
for C18H14ClNOS (Mr = 327) are: C, 66.05; H, 4.28; N, 4.28; S, 




0.9651 g (79 %); Yellow solid; m.p 182–184 °C; IR (KBr) νmax / 
cm–1: 3296 (N-H), 1628 (C=O); 1H NMR (300 MHz, CDCl3)  
δ / ppm: 2.17 (q, 2H, C4-H, J = 5.3 Hz), 3.06 (t, 2H, C3-H2, J = 
5.4 Hz), 3.13 (t, 2H, C5-H2, J 6.3 Hz), 7.04-7.80 (m,7H, 
C3’,C4’,C5’-thiophene-H; C2-methylene-H, C1,C3,C4-aromatic-
H ), 9.02 (s,N-H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 25.3, 
26.3, 27.9, 112.5, 112.9, 120.5, 122.5, 125.7, 126.9, 127.5, 
129.3, 130.2, 133.2, 133.9, 134.9, 136.3, 138.7, 185.4; Anal. 
Calcd mass fractions of element, w / %, for C18H14BrNOS: 
(Mr = 371) are: C, 58.22; H, 3.77; N, 3.77; S, 8.62. Found: C, 
58.20; H, 3.72; N, 3.80; S, 8.62. 
 
General Procedure for the Synthesis of 
Compounds (4a–4d) 
Respective 7-thiophen-2-ylmethylene-7,8,9,10-tetrahydro-
5H-cyclohepta[b]indol-6-one (3a, 1 mmol) was dissolved in 
absolute ethanol (20 mL) and hydrazine hydrate (0.5 mL,  
10 mmol) was added. This mixture was refluxed in oil bath 
for 30 minutes. Then the solvent was removed under 
reduced pressure. The crude reaction mixture was poured 
into ice cold water and the solid obtained was filtered off, 
washed with water, dried and purified over column 
chromatography with petroleum ether: ethyl acetate 
mixture (1 : 2), to get 4a as a yellow prism. Compounds 4b–
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0.1781 g (79 %); Yellow prism; m.p 150–152 °C; IR (KBr) νmax / 
cm–1: 3427 (N-H); 1H NMR (400 MHz, CDCl3) δ / ppm: 1.63 
(q, 2H, C4-H, J = 8.8 Hz), 2.13 (t, 2H, C3-H2, J = 8.4 Hz), 2.89 
(t, 2H, C5-H2 J = 7.6 Hz), 6.93-7.74 (m, 7H, C3’,C4’,C5’-
thiophene-H; C7,C8,C9,C10-aromatic-H), 7.95 (s, 1H, 2NH); 
10.95 (s, N-H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 26.1, 
27.0, 27.8, 109.1, 109.4, 112.3, 116.6, 120.3, 121.6, 122.3, 
123.8, 125.8, 126.8, 128.5, 136.7, 149.5, 152.7, 157.6; Anal. 
Calcd mass fractions of element, w / %, for C18H15N3S (Mr = 
305) are: C, 70.82; H, 4.92; N, 13.77; S, 10.49. Found: C, 
70.80; H, 4.91; N, 13.75; S, 10.47. 
 
8-METHYL-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-4H-
PYRAZOLO[4’,3’:6,7] CYCLOHEPTA[1,2-b]INDOLE (4b) 
0.1732 g (75 %);Yellow prism; m.p 164–166 °C; IR (KBr) νmax / 
cm–1: 3366 (N-H); 1H NMR (400 MHz, CDCl3) δ / ppm: 1.70 
(q, 2H, C4-H, J = 10.4 Hz), 2.14 (t, 2H, C3-H2, J = 10.8Hz), 2.43 
(s, 1H, C7-CH3), 3.17 (t, 2H, C5-H2 J = 6.4Hz), 6.51–7.71 (m, 
6H, C3’,C4’,C5’-thiophene-H; C7,C9,C10-aromatic-H); 8.06 (s, 
1H, 2NH); 11.32 (s, N-H); 13C NMR (75.4 MHz, CDCl3) δ / 
ppm: 21.5, 25.8, 26.7, 27.5, 111.4, 112.0, 116.1, 120.5, 
123.1, 123.3, 128.4, 128.5, 129.3, 133.1, 135.2, 136.5, 
144.1, 152.4; Anal. Calcd mass fractions of element, w / %, 
for C19H17N3S (Mr = 319) are: C, 71.47; H, 5.33; N, 13.16; S, 
10.03. Found: C, 71.40; H, 5.32; N, 13.17; S, 10.04. 
 
8-CHLORO-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-4H-
PYRAZOLO[4’,3’:6,7] CYCLOHEPTA[1,2-b]INDOLE (4c) 
0.1794 g (72 %); Yellow prism; m.p 180-182 °C; IR (KBr) νmax / 
cm–1: 3375 (N-H); 1H NMR (400 MHz, CDCl3) δ / ppm: 1.61 
(q, 2H, C4-H, J = 10.0 Hz), 2.12 (t, 2H, C3-H2, J = 8.8 Hz), 2.90 
(t, 2H, C5-H2 J = 8.0 Hz), 6.94–7.85 (m, 6H, C3’,C4’,C5’-
thiophene-H; C7,C9,C10-aromatic-H), 8.09 (s, 1H, 2NH); 
11.20 (s, N-H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 25.6, 
26.6, 27.3, 112.2, 113.0, 113.3, 116.7, 122.6, 123.8, 123.9, 
129.3, 129.8, 133.8, 135.2, 136.0, 144.4, 152.2, 158.6; Anal. 
Calcd mass fractions of element, w / %, for C18H14ClN3S (Mr = 
339) are: C, 63.71; H, 4.13; N, 12.38; S, 9.43. Found: C, 
63.68; H, 4.09; N, 12.34; S, 9.41. 
 
8-BROMO-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-4H-
PYRAZOLO[4’,3’:6,7] CYCLOHEPTA[1,2-b]INDOLE (4d) 
0.1693 g (64 %); Yellow prism; m.p 172–174 °C; IR (KBr) νmax / 
cm–1: 3297 (N-H); 1H NMR (400 MHz, CDCl3) δ / ppm: 1.70 
(q, J = 10.0 Hz, 2H), 2.09 (t, J = 10.0 Hz, 2H), 2.70 (t, J = 12.4 Hz, 
2H), 6.94–7.83 (m, 6H), 8.05 (s, 1H), 10.99 (s, 1H); 13C NMR 
(75.4 MHz, CDCl3) δ: 25.9, 26.6, 27.5, 112.4, 113.3, 113.6, 
116.6, 122.4, 123.8, 123.9, 129.3, 129.8, 133.4, 135.1, 136.2, 
144.3, 152.3, 158.7; Anal. Calcd mass fractions of element,  
w / %, for C18H14BrN3S: (Mr = 384) are: C, 56.25; H, 3.64; N, 
10.93; S, 8.33. Found: C, 56.23; H, 3.62; N, 10.89; S, 8.31.  
General Procedure for the Synthesis of 
Compounds (5a–5d) 
7 - Thiophen - 2 - ylmethylene - 7, 8, 9, 10 - tetrahydro - 5H - cyclo-
hepta[b]indol-6-one (3a, 1 mmol) was mixed with hydroxyl-
amine hydrochloride (14 mmol) and pyridine (5 mL). The 
reaction mixture was refluxed in oil bath for 30 minutes. 
After the reaction was completed, the mixture was poured 
into crushed ice. The resulting solid separated was filtered 
off, washed with dilute HCl and water. The substance was 
dried and purified over column chromatography with 
petroleum-ether: ethyl acetate solvent mixture (1 : 5), to 
get 5a as a yellow prism. Compounds 5b–5d was prepared 
using a similar procedure. 
 
3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-
ISOXAZOLO[4’,3’:6,7]CYCLOHEPTA[1,2-b] INDOLE (5a) 
0.1552 g (57 %); Yellow prism; m.p 152–154 °C; IR (KBr) νmax / 
cm–1: 3292 (N-H), 1739 (C=O); 1H NMR (400 MHz, CDCl3)  
δ / ppm: 1.63 (q, 2H, C4-H, J = 8.8 Hz), 2.13 (t, 2H, C3-H2, J = 
8.4 Hz), 2.89 (t, 2H, C5-H2 J = 7.6 Hz), 6.93-7.74 (m,7H, 
C3’,C4’,C5’-thiophene-H; C7,C8,C9,C10-aromatic-H ), 10.95 (s, 
N-H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 22.6, 25.6, 26.5, 
109.4, 109.7, 112.0, 116.3, 120.6, 121.8, 122.1, 137.3, 
141.5, 143.7, 145.6, 147.0, 151.8, 156.6, 157.8; Anal. Calcd 
mass fractions of element, w / %, for C18H14N2OS (Mr = 306) 
are: C, 70.58; H, 4.57; N, 9.15; S, 10.45. Found: C, 70.55; H, 
4.52; N, 9.17; S, 10.42. 
 
8-METHYL-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-
ISOXAZOLO[4’,3’:6,7]CYCLOHEPTA [1,2-b]INDOLE (5b) 
0.1530 g (58 %); Yellow prism; m.p 167–169 °C; IR (KBr) νmax / 
cm–1: 3293 (N-H), 1741 (C=O); 1H NMR (400 MHz, CDCl3)  
δ / ppm: 1.70 (q, 2H, C4-H, J = 10.4 Hz), 2.14 (t, 2H, C3-H2,  
J = 10.8 Hz), 2.43 (s, 1H, C7-CH3), 3.17 (t, 2H, C5-H2 J =  
6.4 Hz), 6.51–7.71 (m, 6H, C3’,C4’,C5’-thiophene-H; C7,C9,C10-
aromatic-H), 11.32 (s, N-H). 13C NMR (75.4 MHz, CDCl3) δ / 
ppm: 21.6, 25.8, 26.6, 27.5, 111.9, 119.1, 121.4, 122.0, 
126.4, 127.2, 127.8, 128.4, 130.5, 136.3, 136.5, 137.0, 
139.8, 150.1, 157.6; Anal. Calcd mass fractions of element, 
w / %, for C19H16N2OS (Mr = 320) are: C, 71.25; H, 5.00; N, 
8.75; S, 10.00. Found: C, 71.29; H, 4.98; N, 8.71; S, 10.02. 
 
8-CHLORO-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-
ISOXAZOLO[4’,3’:6,7]CYCLOHEPTA [1,2-b]INDOLE (5c) 
0.1603 g (55 %); Yellow prism; m.p 172–174 °C; IR (KBr) νmax / 
cm–1: 3285 (N-H), 1741 (C=O); 1H NMR (400 MHz, CDCl3)  
δ / ppm: 1.61 (q, 2H, C4-H, J = 10.0 Hz), 2.12 (t, 2H, C3-H2,  
J = 8.8 Hz), 2.90 (t, 2H, C5-H2 J = 8.0 Hz), 6.94–7.85 (m,6H, 
C3’,C4’,C5’-thiophene-H; C7,C9,C10-aromatic-H), 11.20 (s, N-
H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 25.9, 26.6, 27.5, 
113.5, 115.8, 117.4, 120.2, 121.5, 122.5, 126.7, 136.4, 
137.8, 139.8, 141.6, 141.7, 141.8, 152.3, 158.7; Anal. Calcd 
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340) are: C, 63.52; H, 3.82; N, 8.23; S, 9.41. Found: C, 63.50; 
H, 3.78; N, 8.25; S, 9.39. 
 
8-BROMO-3-THIOPHEN-2-YL-2,5,6,11-TETRAHYDRO-
ISOXAZOLO[4’,3’:6,7]CYCLOHEPTA [1,2-b]INDOLE (5d) 
0.1594 g (51 %); Yellow prism; m.p 168–170 °C; IR (KBr) νmax / 
cm–1: 3286 (N-H), 1740 (C=O); 1H NMR (400 MHz, CDCl3)  
δ / ppm: 1.70 (q, 2H, C4-H, J = 10.0 Hz), 2.09 (t, 2H, C3-H2,  
J = 10.0 Hz), 2.70 (t, 2H, C5-H2 J = 12.4 Hz), 6.94-7.83 (m,6H, 
C3’,C4’,C5’-thiophene-H; C7,C9,C10-aromatic-H ), 10.99 (s, N-
H); 13C NMR (75.4 MHz, CDCl3) δ / ppm: 25.6, 26.6, 27.3, 
113.6, 120.3, 121.4, 122.5, 124.5, 126.8, 127.1, 128.8, 
130.5, 133.8, 135.2, 136.0, 144.4, 152.2, 158.6; Anal. Calcd 
mass fractions of element, w / %, for C18H13BrN2OS (Mr = 
385) are: C, 56.10; H, 3.37; N, 7.32; S, 8.31. Found: C, 56.10; 
H, 3.37; N, 7.32; S, 8.31. 
 
General Procedure for the Synthesis of 
Compounds (6a–6d) 
7 – Thiophen – 2 – ylmethylene - 7, 8, 9, 10 – tetrahydro - 5H - 
cyclo-hepta[b]indol-6-one (3a, 1 mmol) was mixed with 
guanidium nitrate (10 mmol) in glacial acetic acid (5 mL). 
The reaction mixture was refluxed in oil bath for 5 hours. 
The reaction was monitored by TLC. After the reaction was 
completed, the mixture was poured into crushed ice. The 
resulting solid separated was filtered off, washed with 
water. The substance was dried and purified over column 
chromatography with petroleum-ether: ethyl acetate 
solvent mixture (5 : 1), to get 6a as a yellow solid. Com-
pounds 6b–6d was prepared using a similar procedure. 
 
2-AMINO- 4-THIOPHEN-2-YL-5,6,7,12-TETRAHYDRO-
PYRIMIDO[5’,6’:6,7]CYCLOHEPTA [1,2 b]INDOLE (6a) 
0.1971 g (70 %); Yellow solid; m.p 138-140 °C; IR (KBr) νmax / 
cm–1: 3342 (N-H), 3275, 3196 (NH2); 1H NMR (400 MHz, 
CDCl3) δ / ppm: 1.87–1.88 (m, 2H, C4-H), 1.94–1.99 (m, 2H, 
C3-H2), 2.75–2.73 (m, 2H, C5-H2), 5.00 (s, 2H, NH2), 6.92–
7.57 (m,7H, C3’,C4’,C5’-thiophene-H; C8,C9,C10,C11-aromatic-
H ), 11.22 (s, N-H); 13C NMR (100.6 MHz, CDCl3) δ / ppm: 
23.6, 26.8, 29.7, 113.3, 121.0, 122.7, 123.2, 126.8, 128.6, 
129.0, 129.1, 136.9, 140.5, 140.6, 142.1, 143.8, 150.0, 
154.2, 155.2; Anal. Calcd mass fractions of element, w / %, 
for C19H16N4S (Mr = 332) are: C, 68.67; H, 4.81; N, 16.86; S, 





0.1938 g (68 %); Yellow solid; m.p 189–191 °C; IR (KBr) νmax / 
cm–1: 3351 (N-H), 3289, 3190 (NH2); 1H NMR (400 MHz, 
CDCl3) δ / ppm: 1.87–1.88 (m, 2H, C4-H), 1.94–1.97 (m, 2H, 
C3-H2), 2.37–2.75 (m, 2H, C5-H2), 5.00 (s, 2H, NH2), 6.92–
7.46 (m,6H, C3’,C4’,C5’-thiophene-H; C8,C10,C11-aromatic-H ), 
11.17(s, N-H); 13C NMR (100.6 MHz, CDCl3) δ / ppm: 21.16, 
23.6, 26.8, 29.7, 113.3, 121.0, 122.7, 123.2, 126.8, 128.6, 
129.0, 129.1, 136.9, 140.5, 140.6, 142.1, 143.8, 150.0, 
154.2, 155.2 ppm; Anal. Calcd mass fractions of element,  
w / %, for C20H18N4S (Mr = 346 ) are: C, 69.36; H, 5.20; N, 





0.1860 g (71 %); Yellow solid; m.p 218–220 °C; IR (KBr) νmax / 
cm–1: 3322 (N-H), 3267, 3176 (NH2); 1H NMR (400 MHz, 
CDCl3) δ / ppm: 1.87–1.88 (m, 2H, C4-H), 1.94–1.99 (m, 2H, 
C3-H2), 2.73–2.75 (m, 2H, C5-H2), 5.00 (s, 2H, NH2), 6.92–
7.57 (m,6H, C3’,C4’,C5’-thiophene-H; C8,C10,C11-aromatic-H ), 
11.22(s, N-H); 13C NMR (100.6 MHz, CDCl3) δ / ppm: 25.4, 
25.7, 26.4, 113.5, 121.1, 122.5, 123.9, 126.3, 128.9, 129.0, 
129.5, 136.8, 140.6, 140.6, 142.1, 143.8, 150.0, 154.2, 
155.3; Anal. Calcd mass fractions of element, w / %, for 
C19H15ClN4S (Mr = 366) are: C, 62.29; H, 4.09; N, 15.30; S, 





0.1702 g (65 %); Yellow solid; m.p 212–214 °C; IR (KBr) νmax / 
cm–1: 3345 (N-H), 3269, 3144 (NH2). 1H NMR (400 MHz, 
CDCl3) δ / ppm: 1.87–1.88 (m, 2H, C4-H), 1.94–1.99 (m, 2H, 
C3-H2), 2.73–2.75 (m, 2H, C5-H2), 5.00 (s, 2H, NH2), 6.92–
7.57 (m,6H, C3’,C4’,C5’-thiophene-H; C8,C10,C11-aromatic-H ), 
11.21(s, N-H); 13C NMR (100.6 MHz, CDCl3) δ / ppm: 25.3, 
25.6, 26.4, 113.5, 121.1, 122.5, 123.9, 126.3, 128.9, 129.0, 
129.5, 136.8, 140.6, 140.6, 142.1, 143.8, 150.0, 154.2, 
155.3; Anal. Calcd mass fractions of element, w / %, for 
C19H15BrN4S (Mr = 411) are: C, 55.47; H, 3.64; N, 13.62; S, 
7.78. Found: C, 55.45; H, 3.68; N, 13.60; S, 7.72. 
In vitro Antibacterial Studies 
All the cyclohepta[b]indole derivatives were studied for 
their antibacterial activity against clinically isolated two 
Gram-positive bacteria (Bacillus subtilis (B.S) and Staphylo-
coccus aureus (S.A)) and five Gram negative bacteria (Esch-
erichia coli (E.C), Proteus vulgaris (P.V), Salmonella typhi 
(S.T), Pseudomonas aureus (P.A) and Klebsiella pneumonia 
(K.P)) using conventional agar dilution method.[14] The min-
imum inhibitory concentrations (MICs) values were deter-
mined by comparing the values with reference bacterial 
drugs as Sparfloxacin and Norfloxacin. All the cultures were 
prepared by Muller Hinton agar and the turbidity of all bac-
terial cultures was adjusted to 0.5 McFarland standards by 
preparing a bacterial suspension of three to five well-iso-
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from an agar plate culture. The cultures were further 
diluted 1,000-fold to get an inoculums size of 1.5×105  
CFU / mL. The synthesized compounds and standard bac-
terial drugs (50 mg) were dissolved in dimethyl forma-
mide (DMF) (0.5 mL) and the solution was diluted with 
water (4.5 mL) to get a stock solution of 10,000 mg L–1 of 
each compound. Further progressive double dilution with 
Muller–Hinton broth was performed to obtain the required 
concentrations of 2,500–2.1 μg mL–1. To make sure that the 
solvent had no effect on the bacterial growth, a control test 
was carried out with a test medium supplemented with 
DMF at the same dilutions as used in the experiment. In 
each microwell inoculated with 75 μL of the serial dilutions, 
75 μL of the bacterial suspension was added in a series of 
12 microwells. Incubation of the cultures overnight at 37 °C 
was done and the growth measured. 
Molecular Docking Studies 
Molecular docking studies were done by the Schrödinger 
Glide program[15] (version 8.5, Schrödinger, LLC, New York 
2010). The three-dimensional structures of CK2 protein 
were predicted and downloaded through Robetta server. In 
order to apprehend the docking glide score results, a Maes-
tro user interface (version 8.5, Schrödinger, LLC, New York 
2010) was executed. To confirm the best docking and to 
validate the docking score, the protocol was evaluated by 
re-docking. Structures of all the compounds were sketched 
using ACD/chemsketch[16] (Freeware version). With the 
help of the Glide Grid generation wizard we can describe 
the docking space which predicts the biologically active site. 
Glide docking was accomplished with the help of SP (Single 
precision) and XP (Extra precision) docking procedure. 
In vitro Anticancer Studies 
The in vitro anticancer property of the synthesized cyclo-
hepta[b]indole derivatives was carried out by MTT assay.[17] 
The human cervical cancer cell line (HeLa) was acquired 
from National Centre for Cell Science (NCCS), Pune, and cul-
tured in complete EMEM growth medium (EMEM + 10 % 
FBS). For screening test, the cells were seeded into 96-well 
plate at plating density of 10,000 cells / wells. And the 
plates were incubated to allow cell attachment at 37 °C,  
5 % CO2, 95 % air and 100 % relative humidity for 24 h. Then 
the cells were treated with the synthesized cyclo-
hepta[b]indole derivatives at different concentrations. The 
samples were dissolved in DMSO and additionally diluted in 
serum free medium to make five concentrations. 100 μL 
per well of each concentration was added to plates to get 
final concentrations of 100, 50, 25, 12.5 and 6.25 µM. The 
total volume in each well was 200 µL and the plates were 
incubated at 37 °C, 5 % CO2, 95 % air and 100 % relative 
humidity for 48 h. The medium without samples were con-
sidered as control. Three replicates were maintained for 
each concentration. After incubation, 15 µL of MTT solution 
(5 mg mL–1) in phosphate buffered saline (PBS) was added 
to each well and incubated for 4 h at 37 °C. The medium 
with MTT was then flicked off and the formed Formosan 
products were dissolved in 100 µL of DMSO and then the 
absorbance was monitored at 570 nm using micro plate 
reader. The % cell inhibition was calculated using the 
following formula. % cell inhibition = 100 - absorbance 
(sample) / absorbance (control) × 100. Nonlinear regression 
graph was plotted against % cell inhibition and Log10 
concentration and using Graph Pad Prism software IC50 
were determined. 
 
RESULTS AND DISCUSSION 
Chemistry 
The precursor thiophen-2-ylmethylene 3a–d was synthe-
sized by mixed aldol condensation of 1,4-dihydro-2H-cyclo-
penta[b]indol-3-one 1a–d with thiophene-2-carbaldehyde 
2. Further the reaction of thiophen-2-ylmethylene deriva-
tives 3a–d with hydrazine hydrate, hydroxylamine hydro-
chloride and guanidium nitrate leads to highly substituted 
cyclohetpa[b]indoles 4a–d, 5a–d and 6a–d in one-pot addi-
tion reactions. The synthetic routes are shown in the 
Scheme 1. The structures of the products were established 
on the basis of IR, 1H NMR, 13C NMR data and elemental 
analysis. 
 The formation of 3a was confirmed from its 1H NMR 
spectrum, which shows that the C2-methylene proton and 
thiophene-CH signals along with the aromatic proton sig-
nals and the disappearance of C7-methylene proton signal. 
The IR spectrum of 3a showed sharp and strong bands at 
3312 and 1623 cm–1 assigned to NH and carbonyl group 
respectively. The spectral and analytical data suggested the 
structure of 3a to be a thiophen-2-ylmethylene compound. 
The proton NMR spectrum of 4a showed two broad singlet 
at 10.95 ppm and 7.77 ppm, attributed to indole-NH and 
pyrazole-NH protons, respectively. The other aromatic pro-
tons appeared as multiplet in the region 6.93–7.54 ppm 
which confirmed the formation of 4a. The IR spectrum of 
5a registered absorption band at 1626 cm–1 assigned to 
C=N functional group. Its proton NMR spectrum showed 
one broad singlet at 11.55 ppm assigned for indole-NH. The 
rest of the aromatic protons appeared as a multiplet be-
tween the regions δ 7.05–7.90 ppm. Analytical data are in 
accordance with the proposed structure for compound 5a. 
 The 1H NMR spectrum of 6a showed a broad singlet 
at 11.22 ppm accounted for indole-NH. The methylene 
protons disappeared from the aliphatic region and further 
peaks appeared in the aromatic region undoubtedly 
indicating that the system was completely aromatized. The 
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a) R = H
b) R = CH3
c) R = Cl












6 a-d5 a-d  
Scheme1. Synthesis of substituted cyclohetpa[b]indoles. 
 
Table 1. In-vitro antibacterial activity of synthesized compounds against (MICs in μg mL–1). 
Compounds 
Minimum Inhibitory Concentrations / μg mL–1 (MIC) 
B. subtilis S. aureus E. coli P. vulgaris S. typhi P. aureus K. pneumoniae 
3a 286.3 –(a) 483.1 246.4 237.2 106.8 724.6 
3b 396.5 638.2 273.7 485.6 547.1 162.5 366.5 
3c 174.0 724.6 –(a) 196.5 321.3 141.1 994.2 
3d –(a) 173.7 326.8 661.5 799.7 131.7 –(a) 
4a 263.5 564.0 291.6 81.5 166.5 116.5 1012.4 
4b 82.0 –(a) 163.5 361.5 –(a) 156.5 876.5 
4c 39.5 162.5 –(a) 157.5 443.5 83.5 572.5 
4d 157.2 234.5 89.5 132.5 101.7 112.5 890.5 
5a 218.3 146.5 –(a) 247.5 543.5 56.2 513.5 
5b 84.25 113.5 427.25 143.8 282.6 97.5 970.5 
5c 85.0 –(a) 126.3 291.4 –(a) 156.3 1280.6 
5d 61.9 264.6 105.2 349.5 784.4 39.7 1957.1 
6a 246.4 185.6 116.5 161.5 197.7 107.5 836.8 
6b 237.2 247.1 121.3 99.7 246.3 161.5 179.5 
6c 106.8 212.5 –(a) 231.7 593.5 180.0 714.5 
6d 124.6 166.5 94.2 128.3 438.5 31.2 472.5 
Sparfloxacin(b) 9.76 4.97 166.3 7.8 1500 163.8 1320.0 
Norfloxacin(b) –(a) 49.06 515 392.25 825 57.4 973.4 
Lower MIC values indicate that higher antimicrobial activity. 
(a) No inhibition observed. 
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from a broad singlet at 5.00 ppm. The IR spectrum showed 
absorptions at 3443, 3189 and 3157 cm–1 which were 
assigned to N–H and NH2 functional groups. Analytical data 
are in accordance with the proposed structure for 
compound 6a. The 13C NMR spectra of the compounds are 
characteristic and helped in assigning the number of 
different carbon atoms. The structures of the other 
compounds were assigned in similar way with all spectral 
and analytical data. 
In vitro Evaluation of Antibacterial 
Activities 
The newly synthesized cyclohepta[b]indole derivatives 
were tested for their in vitro antibacterial activities against 
two Gram-positive and five Gram-negative bacteria strains. 
The results revealed that the derivatives exhibited good 
antibacterial profile against three Gram-negative bacteria 
S. typhi, P. aureus and K. Pneumonia. Compounds 4d  
(89.5 μg mL–1) and 6d (94.2 μg mL–1) exhibit better activity 
against E. coli than the standard drug Sparfloxacin  
(166.3 μg mL–1) and Norfloxacin (515 μg mL–1). Compound 
4a (81.5 μg mL–1) exhibits better antibacterial activity 
against P. vulgaris than Norfloxacin (627 μg mL–1). Com-
pound 4d (101.7 μg mL–1) shows good activity against S. 
typhi. Compound 6b (179.5 μg mL–1) exhibits the best activ-
ity among all the molecules synthesized against K. 
pneumoniae that was better than those of Sparfloxacin 
(1320 μg mL–1) and Norfloxacin (973 μg mL–1). Standard 
drug Norfloxacin did not exhibit any activity against  
B. subtilis microorganism. Compounds 4b and 5c did not ex-
hibit any inhibition against S. typhi and P. aureus. All the 
MIC values are presented in Table 1. 
 Regarding the structure activity relationship (SAR), a 
variety of 8-substituted cyclohepta[b]indole analogues 
containing CH3, Cl, Br groups have been exploited for their 
antibacterial activity. The investigation reveals that intro-
duction of halogen (chloro and bromo) groups positively in-
fluence the antibacterial effectiveness. This property is 
truly aligned with the literature.[18] Further compound with 
an unsubstituted cyclohepta[b]indole ring exhibited only 
least activity. Figure 1 clearly shows this pattern among 
pyrazolo derivatives 4a–4d. 
 The pyrazole moiety[19] enhances antibacterial activity 
in 4a–d, inducing better antibacterial activity against four 
bacterial pathogens when compared to all other compounds. 
Only a moderate improvement of antibacterial activity was 
noted in the presence of a isoxazole 5a–d or pyrimidine 
moiety 6a–d. Compounds 3a–d showed the least activity 
among the series. Representative antibacterial activities of 
most potent compounds are displayed in Figure 2. 
Molecular Docking Studies 
In an attempt to get deeper understanding about the mech-
anism of anticancer activity and structure activity relation-
ships (SAR) of the newly synthesized hetero-annulated 
cyclohepta[b]indoles, we performed docking studies using 
the Schrödinger Glide program with Human Protein Kinase 
CK2 protein. It is a ubiquitous serine/threonine protein 
kinase, product of a tetramer containing two catalytic and 
regulatory subunits (α and / or α’) linked with two mole-
cules of the β subunits. CK2 is a multifunctional protein ki-
nase that plays a major role in cell growth, cell proliferation 
and cell apoptosis. Numerous reports have demonstrated 
the over-expression, dysregulation and hyperactivation of 





















4c 4a4b4d  
Figure 1. Role of electron-withdrawing group in increasing the efficiency of antibacterial activities. 
 
 
Figure 2. Representative antibacterial activities of most 
potent compounds. 
 
Table 2. Molecular docking data of compounds (4c, 5c and 
6c) with protein kinase CK2.  
Compound Glide score / 
kcal mol–1 
E model score Glide energy 
4c –7.081 –53.589 –37.755 
5c –7.298 –53.162 –36.784 
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 The glide and E model scores of the selected com-
pounds (4c, 5c and 6c) are presented in Table 2. The dock-
ing results show that the binding mode in compound 4c was 
attractively bound to CK2 via hydrophobic interaction, and 
Pi-Pi stacked interaction. The compound 4c enclosed by 
VAL27, VAL35, ALA50, LEU151, ALA165, ILE79, LEU70, 
MET167, PHE169, TYR32. The amino acid residue PHE97 in-
teracts in pi-pi stacked interaction with thiophene ring. 
VAL27, VAL35, LEU151, ALA50, ILE79, PHE97, MET167, 
LEU70, PHE169, ALA165, TYR32 residues are enclosed by 
hydrophobic interaction in compound 5c. The compound 
6c is surrounded by hydrophobic interaction of amino acids 
residues PHE169, LEU70, ALA165, VAL27, MET167, ILE79, 
PHE97, ALA50, LEU151, and VAL35. The Tyrosinal interacts 
in pi-pi stacked interaction with pyrimidine ring (Figure 3).  
 The scoring functions of the docking program ranked 
that the binding interactions of the intermediate were less 
than those of the cyclised products. The compounds 6a, 6b, 
6c and 6d showed better binding interaction compared to 
the intermediate; this might be due to the presence of the 
pyrimido group. The next best interactions were found 
among the compounds 5a, 5b, 5c and 5d which hold the 
isoxazolo moiety. Among the cyclised products, compound 
6c showed the best lowest binding energy and ligand 
efficiency, this might be due to the presence of the 
pyrimido group which was further reinforced by favourable 
electrostatic interaction of the chloro group at the 9 
position of the indole moiety. In general it was found that 
the pyrimido moiety favours better binding interactions 
compared to isoxazolo, pyrazolo moieties and interme-
diates. 
Anticancer Properties of 
Cyclohepta[b]indole Derivatives 
The in vitro anticancer activities of the synthesized com-
pounds (3a–6d) were evaluated by a cell viability assay 
method against a human cervical cancer cell line (HeLa). A 
clinically used antitumor agent Ellipticine was used as a 
positive control. The anticancer properties of these com-
pounds were shown by IC50 (the concentration that causes 
a 50 % reduction of the cell growth). The results are given 
in Figure 4. The in vitro anticancer assay proves that the 
compounds 5c, 6c and 6d have potent anticancer effect on 
human cervical cancer cells. The estimated IC50 values were 
17.14 µM for 5c, 12.92 µM for 6c, 13.06 µM for 6d. There-
fore, it is evident that the compound 6c has a cell growth 
inhibition value closer to the standard drug Ellipticine. From 
the Figure 5, it is evident that all the compounds display a 
dose-dependent anticancer activity. The maximum anti-
cancer property was obtained at 100 μM. The percentage 
of cell growth inhibition is found to be 58.26 % for com-
pound 5c, 88.13% for compound 6d and 100 % for com-
pound 6c. 
 
Figure 3. Docking model structure of compounds 4c, 5c and 
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Structure Activity Relationship (SAR) 
Studies 
The present study evaluates the effect of several 
substituents and from the results of anticancer activity of 
the synthesized cyclohepta[b]indoles the following 
structure activity relationships can be derived: 
 (i) Among the synthesized compounds, the 
compound 6c displayed the strongest anticancer activity 
against HeLa. This might be due to the presence of the 
pyrimido moiety[22] which enhanced the anticancer activity. 
The biological properties like anticancer, antiviral, 
antibacterial, urinary tract infection treatment and 
vasodilation were improved when the 5 and 6 position of 
pyrimidine fused with heterocyclic ring. Literature survey 
revealed that the pyrimidine substituted heterocycles 
induced cell apoptosis through tubulin polymerization. The 
structure activity relationship analysis also confirms that 
pyrimidine group is essential for the induction of apoptosis 
and extreme anticancer activity.[23] 
 (ii) The next most active compounds were 5a, 5b, 5c 
and 5d which displayed good anticancer activity. This might 
be due to the presence of an isoxazolo group[24] which 
boosts the anticancer activity.  
 (iii) Subsequently, compounds 4a, 4b, 4c and 4d also 
showed good anticancer activity with IC50 values < 65 μM 
against HeLa which was due to the presence of pyrazolo 
moiety which enhanced the anticancer activity. 
 (iv) It was noted that the intermediates showed 
comparatively less cytotoxic activity than the cyclised 
derivatives (Figure 6). 
 (v) In general, it was noted that among the cyclised 
derivatives, the derivatives bearing an electron-
withdrawing[25] chlorine and bromine in the indole ring 
enhanced the anticancer activity more than the electron-
donating methyl group and the unsubstituted derivative. 
 
CONCLUSION 
Molecular docking study results revealed clearly that these 
molecules show significant molecular binding interaction 
with Protein kinase CK2. The structure activity relationship 
 
 
Figure 4. Anticancer activity (IC50)of synthesised compounds 
(3a–6d) and Ellipticine used as standard. 
 
Figure 5. Effect of % cell growth inhibition of the compounds 
5c, 6c and 6d in different concentration (μM). 
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of antimicrobial studies discovered that the halogen 
substituted cyclohepta[b]indoles display higher activity 
than their counterparts. Similarly, compounds 5c, 6c and 6d 
displayed better anticancer activity against other 
derivatives. Further investigations of cyclohepta[b]indole 
derivatives could lead to more potent compounds as 
promising candidates for the development of new 
antimicrobial and anticancer agents. 
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